Article

# MS/MS-guided isolation of clarinoside, a new anti-inflammatory pentalogin derivative

Coralie Audoin <sup>1</sup>, Adam Zampalégré <sup>1</sup>, Natacha Blanchet <sup>1</sup>, Alexandre Giuliani <sup>2,3</sup>, Emmanuel Roulland <sup>4</sup>, Olivier Laprévote <sup>4,5</sup> and Grégory Genta-Jouve <sup>4,\*</sup>

- Laboratoires Clarins, 5 rue Ampère, 95300 Pontoise, France;
- <sup>2</sup> DISCO Beamline, Synchrotron SOLEIL, 91192, Gif-sur-Yvette, France;
- <sup>3</sup> UAR1008, CEPIA, INRA, 44316 Nantes, France;
- 4 C-TAC, UMR 8638 CNRS, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie de Paris, 4 avenue de l'Observatoire, 75006 Paris, France;
- Department of Biochemistry, Hôpital Européen Georges Pompidou, AH-HP, 75015 Paris, France
- \* Correspondence: gregory.genta-jouve@parisdescartes.fr; Tel.: +33 173 531 585
- Abstract: Re-investigation of the chemical composition of the annual plant Mitracarpus scaber
- Zucc. led to the identification of c larinoside, a new p entalogin d erivative c ontaining a rare
- quinovose moiety, and the known compound harounoside. While the planar structure was fully
- determined using tandem MS and quantum mechanics calculations (QM), the tridimensional
- structure was unravelled after isolation and NMR analysis. The absolute configuration was assigned
- 6 by comparison of experimental and theoretical SRCD spectra. Both compounds were tested
- for anti-inflammatory a ctivity and compound 1 showed the ability to inhibit the production of
- interleukin-8 (II-8) with an IC<sub>50</sub> of 9.17  $\mu$ M
- Keywords: Mitracarpus scaber Zucc.; pentalogin; anti-inflammatory; MS/MS; Il-8;

## 1. Introduction

Mass spectrometry has become a very convenient technique for the targeted search of new bioactive metabolites[1,2] and the recent introduction of the Global Natural Product Social molecular networking (GNPS) Web-platform (http://gnps.ucsd.edu) has enabled the quick and automatic 13 spectral mining of MS/MS spectra [3]. In our ongoing research for bioactive compounds, we decided 14 to re-investigate the chemical composition of Mitracarpus scaber Zucc. using a MS/MS-guided approach. M. scaber is an annual plant used in African traditional medicine endowed with antifungal, antimicrobial and anti-inflammatory properties [4,5]. Indeed, in West Africa, the leaves of M. scaber are widely used for headache, toothache, amenorrhea, dyspepsia, hepatic diseases, venereal diseases, leprosy and for the treatment of skin diseases such as scabies, infectious dermatitis and eczema. 19 It is well known to contain phenols[5], flavonoid glycosides[5], furanocoumarines[5], terpenes[6], alkaloids[7] and pentalongin derivatives[8,9]. Herein, we report the identification of clarinoside (1), a new pentalongin derivative exhibiting the rare quinovose moiety along with the known harounoside (2). Both compounds were tested for anti-inflammatory activity by evaluating their ability to inhibit the production of interleukin-8 (Il-8).

Figure 1. Structure of clarinoside (1) and harounoside (2)

## 2. Results

27

28

29

30

32

33

35

The analysis started by the creation of a molecular network of the ethanolic extract of M. scaber. The data-dependent analysis (DDA) LC-MS/MS data were uploaded to the GNPS platform and a network was generated using the parameters listed in the materials and method section below (Figure 2). As an anchor (reference) compound, harounoside (2) was used. Its node was quickly "illuminated" using the high resolution MS data and fragmentation pattern. The m/z value at 561.159 corresponding to the  $[M+Na]^+$  adduct of 2 was identified and two diagnostic MS/MS fragments were present on the spectrum (see supporting information): a first one resulting from the cleavage of the glycosidic bond between the aglycone and a glucose moiety at m/z 399.1080  $[M-Glc+Na]^+$  and a second one at m/z 236.0452 resulting from the cleavage of the second O–C between the aglycone and the other glucose  $[M-2Glc+Na]^{\bullet+}$ . In order to seek the structurally related compounds, the cluster was further studied by annotating the edges with m/z differences corresponding to known (bio)chemical modifications implemented in the MetaNetter 2 package [10]. Out of the 307 nodes of the network, one node directly connected to harounoside (2) with a m/z difference of -15.995 attracted our attention. According to the biotransformation list available in the MetaNetter package, this difference corresponded to a dehydroxylation.




Figure 2. Selected cluster containing clarinoside (1) and harounoside (2)

41

45


46

49

50

51

Considering the structure of 2, the dehydroxylation could occur at several positions of each of the two sugars; in order to know on which side of the compound 2 the dehydroxylation site was located, the fragmentation of both glucose moieties was studied using quantum mechanics (QM). After examination of the MS/MS spectrum, the sequential losses of two glucoses were observed. The nature of the sugar being the same at C-5 and C-10, the energy level of the two O-C bonds was only related to the position on the aglycone. In order to confirm that hypothesis, the energy profile of the homolytic dissociation was predicted using the B3LYP method at the STO-3G level (See supporting information). The calculations predicted a difference of ca. +2.5 eV in favor of the O-C1", indicating that the first fragment observed at m/z 399.1080 was related to the loss of one glucose at C-10. This energy difference was very supportive; based on these theoretical results, an energy resolved mass spectrometry (ERMS) study [11] was undertaken in order to determine the stability of the two O-C bonds (O–C1" and O–C1') of compound 2. After selection of the parent ion at m/z 561.16, the intensity of the ion at m/z 399.11 was recorded using an increasing value of collision energy (CID). After the complete extinction of the parent ion (figure 3A), the daughter ion at m/z 399.11 was then fragmented into one major ion at m/z 185.04 using the same approach (figure 3B). As shown in Figure 3, the O–C1' bond linking the aglycone to the glucose moiety is weaker than the O-C1" as it requires a lower CE value for a 50% dissociation (ca. 15 and 17 for O-C1' and O-C1" respectively).



**Figure 3.** Plot of relative ion current versus collision energy corresponding to m/z 561.16 vs 399.10 (**A**) and m/z 399.10 vs 185.04 (**B**); **C**: MS/MS Fragments of **2**. Plot of relative ion current versus collision energy corresponding to m/z 545.16 vs 399.10 (**D**) and m/z 399.10 vs 185.04 (**E**); **F**: MS/MS Fragments of **1**.

The experimental data confirmed the QM predicted values and the same ERMS approach was used for compound **1**. As observed on figures 3D and 3E, an increase of the CE value was required in order to produce the ion at m/z 185.05 (ca. 15 and 18 for O–C1′ and O–C1″ respectively). Those results clearly confirmed the position of the deoxyhexose moiety at C-10. The planar structure was further confirmed by the identification of the neutral loss of 146.0605 Da resulting from the difference between the [M+Na]<sup>+</sup> ion at m/z 545.1685 and the fragment at m/z 399.1080. In parallel with the loss of 162.05 Da corresponding to a glucose moiety (observed for **2**), the loss of 146.0605 was consistent with a deoxyhexose such as fucose, rhamnose or quinovose. Unfortunately, and despite the use of a recent methodology to distinguish the mono-saccharides using MS/MS[12], it was not possible to determine the relative stereo-chemistry of the sugar moieties using MS analysis only, so the isolation of compound **1** was undertaken.

After a reverse phase HPLC purification, 84 mg of compound 1 was obtained and a full set of NMR experiments was performed. The structure of the aglycone was confirmed by comparison of the  $^{1}$ H and  $^{13}$ C NMR chemical shifts (see table 1). The nature of the sugar was determined by taking advantage of the newly published methodology by Giner *et al.*[13] which is based on an acid-promoted hydrolysis of the studied compound performed directly in the deuterated NMR solvent. Looking at the  $^{1}$ H NMR spectrum, the doublets at  $\delta$  4.66 (J = 7.7 Hz) and 4.79 (J = 7.8 Hz) ppm clearly confirmed a glucose and a quinovose moiety (see supporting information). According to the ERMS data, the quinovose was located at C-10 and this was confirmed by the two  $^{3}J$  coupling between H-1'/C-10 and H-1"/C-5 on the HMBC spectrum. The detailed NMR data are given in the table 1.

Table 1. <sup>1</sup> H and <sup>13</sup> C NM	/IR data for <b>1</b> at 600 MHz i	n CD <sub>3</sub> OD ( $\delta_H$ in ppm)
--	------------------------------------	---

clarinoside (1)							harounoside (2) ref [8]		
no.	$\delta_H$ (multiplicity, $J$ )	$\delta_C$	no.	$\delta_H$ (multiplicity, $J$ )	$\delta_C$	no.	$\delta_H$	$\delta_C$	
1	5.29 (dd, 40.7, 13.8 Hz)	65.2	1′	4.66 (d, 7.8)	106.2	1	5.39; 5.30	65.4	
3	6.67 (dd, 14.4, 5.9 Hz)	147.8	2′	3.61 (dd, 9.0, 7.8)	75.9	3	6.68	147.8	
4	6.66 (dd 14.4, 5.9 Hz)	102.1	3′	3.38 (t, 9.0)	77.7	4	6.64	102.2	
4a		121.6	4'	3.11 (t, 9.0)	73.5	4a		121.7	
5		143.3	5′	3.11 (m)	77.8	5		143.4	
5a		131.0	6'	1.21 (d, 5.4)	18.1	5a		131.0	
6	8.43 (d, 8.2 Hz)	124.7	1"	4.79 (d, 7.8)	106.9	6	8.42	124.7	
7	7.44 (dt, 8.2, 1 Hz)	127.0	2"	3.65 (m)	75.8	7	7.43	127.0	
8	7.40 (dt, 8.2, 1 Hz)	126.2	3"	3.46 (m)	71.5	8	7.39	126.3	
9	8.41 (d, 8.2 Hz)	123.7	4"	3.14 (m)	76.9	9	8.43	123.7	
9a	· · · · · · · · · · · · · · · · · · ·	129.1	5"	3.47 (t, 9.0)	78.0	9a		129.1	
10		144.9	6"	3.67 (m)	62.7	10		145.0	
10a		122.6		, ,		10a		122.7	

The absolute configuration of compound 1 was determined by comparison of a synchrotron radiation circular dichroism (SRCD) spectrum with a theoretical electronic circular dichroism (ECD) spectrum (Figure 4). Unexpectedly, the ECD spectrum was quite complex with four Cotton effects (CE) of alternative signs. The calculations were run on the four diasteroisomers, i.e., D-Glc/D-Qui, D-Glc/D-Qui and L-Glc/D-Qui. While the absolute D configuration of the glucose moiety was expected, as it is well known that higher plants produce only this enantiomer [14], the absolute configuration of the quinovose moiety was not obvious because the quinovose can originate from either D-glucose [15] or L-fucose [16].

A very good agreement was observed between the *D*-Glc/*D*-Qui theoretical and the experimental spectra (figure 4). The compound **1** could be named 5,10-dihydroxy-2*H*-naphtho[2,3-b]-pyran-5- $\beta$ -*D*-glucopyranosyl-10- $\beta$ -*D*-quinovopyranoside.

90

93

94





Figure 4. Overlay of SRCD and TD DFT spectra of 1

Both compounds **1** and **2** were tested for anti-inflammatory activity by measuring their ability to inhibit the production of interleukin-8 (Il-8), one of the key mediators associated with inflammation[17,18]. After exposure to the tumor necrosis factor alpha (TNF $\alpha$ ) at 0.5 ng mL<sup>-1</sup> for 24 hours, the production of Il-8 was measured and compared to the known anti-inflammatory standard epigallocatechin gallate (EGCG). As shown in Figure 5, the TNF $\alpha$  is inducing the production of Il-8 of 398.37 $\pm$ 24.09 pg/mg of total protein while the addition of EGCG at 21.8  $\mu$ M allows a return to the basal threshold of 33.01 $\pm$ 2.12 pg/mg of total protein. Although the two compounds were tested



**Figure 5.** Inhibition of the interleukin-8 (Il-8) production: **A** clarinoside (1); **B** harounoside (2); Means  $\pm$  SD are shown. NS. not significant; \*P < 0.05; \*\*\*P < 0.001

during two independent tests, the differences in the measured concentrations (i.e., the production of Il-8 and its inhibition) were observed in both experiments. A good correlation ( $R^2$ =0.996) is observed between the inhibition of the production of Il-8 and the concentration of clarinoside (1). A IC<sub>50</sub> of 9.17

 $\mu$ M was measured while a total inhibition of the II-8 production at 36  $\mu$ M can be extrapolated. The IC<sub>50</sub> of **1** is of the same order of magnitude as that of EGCG (10.9  $\mu$ M[19]), although slightly lower. Interestingly, the IC<sub>50</sub> of **2** (9.21  $\mu$ M), is very similar to the one measured for compound **1**, indicating that the structural modification has no impact on its biological activity.

To conclude, this study enabled the rapid identification of one new compound from *M. scaber*. The biological activity evaluation highlighted the ability of compounds **1** and **2** to inhibit the production of II-8, confirming the importance of *M. scaber* metabolites and their possible uses in cosmetics and personal care products.

## 3. Materials and Methods

## 109 General procedure

100

103

104

105

108

110

111

112

122

126

130

133

135

140

The preparative HPLC was performed on a VWR LaPrep P110 system using a C-630 Büchi UV detector. NMR spectra acquisition was realized using a 600 MHz Bruker Avance spectrometer equipped with Z-gradients and a triple resonance TXI probe. The signals were referenced in ppm to the residual solvent signals (CD<sub>3</sub>OD, at  $\delta_H$  3.31 and  $\delta_C$  49.0). The infra-red spectrum was acquired on a Nicolet IS50 FT-IR spectrophotometer. The specific rotation was measured using a Anton Paar MCP150 polarimeter.

## 116 Plant material

The flowered aerial parts of *Mitracarpus Scaber* were collected in Burkina Faso in the town of Poun and then dried in the same area.

## Extraction and purification

An ethanolic extraction was performed on a 300 g sample of dried plant with a ratio plant/solvent of 1/7 yealding 16.5 g of crude extract which was then directly processed by reverse phase with an XBridge Prep C18, 5  $\mu$ m (OBD 30 × 250 mm) preparative HPLC column. A gradient H<sub>2</sub>O/MeOH (starting from 90:10 to 70/30 in 30 minutes at 100 mL min<sup>-1</sup>) was used to afford the compounds 1 (84 mg) and 2 (113 mg).

## 125 LC-MS data acquisition and processing

A XEVO-G2 XS QTOF (Waters) equipped with an electrospray ionization (ESI) source was used for the qualitative analysis of the extract. A first screening analysis was performed using the  $MS^E$  technology (Waters) on a mass range from 50 to 1500 Da. The optimal ionization source working parameters were as follows: capillary voltage, 3.0 kV; sampling cone, 40 V; extraction cone, 6.0 V; source temperature, 150 °C; desolvation temperature, 600 °C; cone gas flow, 50 L/h; desolvation gas flow, 1000 L/h. MS/MS data were obtained using a data-dependent analysis (DDA) with the same ionization parameters as above using three different collision energies: 10, 20 and 40 V.

## Construction of the molecular network

A molecular network was created using the online workflow at GNPS[3]. The data were filtered by removing all MS/MS peaks within +/- 17 Da of the precursor m/z. MS/MS spectra were window filtered by choosing only the top 6 peaks in the +/- 50 Da window throughout the spectrum. The data were then clustered with MS-Cluster with a parent mass tolerance of 2.0 Da and a MS/MS fragment ion tolerance of 0.5 Da to create consensus spectra. Furthermore, consensus spectra that contained less than 2 spectra were discarded. A network was then created where edges were filtered to have a cosine score above 0.7 and more than 3 matched peaks. Furthermore, edges between two nodes were kept in the network if and only if each of the nodes appeared in each other's respective top 10 most similar nodes. The spectra in the network were then searched against GNPS' spectral libraries. The

library spectra were filtered in the same manner as the input data. All matches kept between network spectra and library spectra were required to have a score above 0.7 and at least 6 matched peaks.

#### Energy resolved mass spectrometry

146

150

151

155

159

160

167

170

171

172

178

180

181

182

183

The LTQ-Orbitrap XL mass spectrometer (Thermo Scientific (Bremen), Bremen, Germany) was used for the ERMS study. The analysis was performed in positive ion mode with a mass range of m/z 100–1100. The optimized ESI parameters were set as follows: capillary temperature of 250 °C; sheath gas (nitrogen) flow of 30 arb.; auxiliary gas (nitrogen) flow of 10 arb.; source voltage of 4.25 kV; capillary voltage of 25 V; tube lens voltage of 110 V. The resolution of the orbitrap mass analyzer was set at 30,000. The isolation width was 2 amu, and the normalized collision energy (CE) was set from 10 to 20. Collision-induced dissociation (CID) was conducted in LTQ with an activation q of 0.25 and activation time of 30 ms. All instruments were controlled by the Xcalibur data system, and the data acquisition was carried out by analyst software Xcalibur (version 2.1) (Waltham, MA, USA) from Thermo Electron Corp.

## Synchrotron Radiation Circular Dichroism

The SRCD experiments were carried out on the SRCD station [20] DISCO beamline [21] at the SOLEIL synchrotron (Gif-sur-Yvette, France). The samples were placed in calcium fluoride cells of 100 microns optical path length and measured at 0.2 mol/l in methanol. (+)-camphor-10-sulfonic acid (CSA) solution was used to calibrate the SRCD signal. For each sample, three spectra were collected in the 350–200 nm range with 1 nm step and 1200 ms integration time. The molar circular dichroism  $\Delta \epsilon$  is expressed in  $M^{-1}$  cm<sup>-1</sup>.

## 163 Computational details

All QM calculations were carried out using Gaussian 16[22]. The energy scan of the C–O bonds was performed using the Hartree–Fock method at the STO-3G level and a 0.1 Å bond length step. The GMMX package was used for the conformational analysis (force field: MMFF94). The TD DFT calculations were performed using the B3LYP method at the 6-31G(d) level for 20 excited states. The SpecDis 1.71 software was used to plot the ECD spectrum[23].

# Cell culture

HaCaT Keratinocytes cells were cultured under standard conditions in DMEM medium supplemented with 10% fetal calf serum. The medium was changed every second day. Confluent cultures were removed by trypsin incubation, and then the cells were counted. They were seeded into 96-well culture microplates at a density of 30,000 cells per well (200  $\mu$  L) and kept at 37 °C for 24 h.

## 175 Interleukine release measurement

The release of IL-8 in cell supernatants was determined by ELISA. After TNF- $\alpha$  incubation (0.5 ng/mL), cell supernatants were harvested and stored at -20 °C until use for measurements. The quantity of released Il-8 was measured according to the manufacturer's instructions (Kit ELISA Human CXCL8 / IL8 R&D Systems). The decrease in Il-8 production by EGCG (10  $\mu$ g/mL) validated the method.

## Statistical analyses

All statistical analyses were performed using R 3.5.0 [24]. Cell samples were analyzed by repeated-measures (n=4) one-way analysis of variance (ANOVA) followed by a Tukey's range test. Significant differences for both clarinoside (1) and harounoside (2) were relative to control as indicated. NS. not significant; \*P < 0.05; \*\*\*P < 0.001

#### Compound Characterization

186

1: White, amorphous solid;  $[\alpha]_D^{20}$  +12.8 (c 0.1, CH<sub>3</sub>OH); UV (DAD)  $\lambda_{max}$  223, 245, 284, 346 nm; 188 <sup>1</sup>H NMR and <sup>13</sup>C NMR data see Table 1; HRESIMS (+) m/z 545.1685 [M + Na]<sup>+</sup> (545,16295 calcd. for C<sub>25</sub>H<sub>30</sub>O12Na,  $\Delta$  -1.8 ppm).

Supplementary Materials: Supplementary materials, including, HRMS, 1D and 2D NMR spectra for compound
 1, and computational details for 2, are available online at www.mdpi.com/link

Acknowledgments: SOLEIL support is acknowledged under proposal number 20170521. We also thank the technical staff of SOLEIL for smooth and efficient running of the facility. The authors are grateful to Pascale Leproux and Karim Hammad for MS and NMR spectra recording. The Région Île de France is also acknowledged for its support through the funding of the DIM Analytics project PRIMEVEGE (ANA2014-ML-001).

Author Contributions: G.G.J. and C.A. conceived and designed the experiments; C.A., A.Z., N.B., E.R. and G.G.J. performed the experiments; C.A., O.L. and G.G.J analyzed the data; A.G. and E.R. contributed reagents/materials/analysis tools; All the authors wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

## Bibliography

- Olivon, F.; Allard, P.M.; Koval, A.; Righi, D.; Genta-Jouve, G.; Neyts, J.; Apel, C.; Pannecouque, C.;
   Nothias, L.F.; Cachet, X.; Marcourt, L.; Roussi, F.; Katanaev, V.L.; Touboul, D.; Wolfender, J.L.; Litaudon,
   M. Bioactive Natural Products Prioritization Using Massive Multi-informational Molecular Networks.
   ACS Chemical Biology 2017, 12, 2644–2651. PMID: 28829118.
- Nothias, L.F.; Nothias-Esposito, M.; da Silva, R.; Wang, M.; Protsyuk, I.; Zhang, Z.; Sarvepalli, A.; Leyssen, P.; Touboul, D.; Costa, J.; Paolini, J.; Alexandrov, T.; Litaudon, M.; Dorrestein, P.C. Bioactivity-Based Molecular Networking for the Discovery of Drug Leads in Natural Product Bioassay-Guided Fractionation. *Journal of Natural Products* 0, 0, null.
- Wang, M.; Carver, J.J.; Phelan, V.V.; Sanchez, L.M.; Garg, N.; Peng, Y.; Nguyen, D.D.; Watrous, J.; Kapono, 3. 209 C.A.; Luzzatto-Knaan, T.; Porto, C.; Bouslimani, A.; Melnik, A.V.; Meehan, M.J.; Liu, W.T.; Crüsemann, M.; 210 Boudreau, P.D.; Esquenazi, E.; Sandoval-Calderón, M.; Kersten, R.D.; Pace, L.A.; Quinn, R.A.; Duncan, K.R.; Hsu, C.C.; Floros, D.J.; Gavilan, R.G.; Kleigrewe, K.; Northen, T.; Dutton, R.J.; Parrot, D.; Carlson, 212 E.E.; Aigle, B.; Michelsen, C.F.; Jelsbak, L.; Sohlenkamp, C.; Pevzner, P.; Edlund, A.; McLean, J.; Piel, J.; Murphy, B.T.; Gerwick, L.; Liaw, C.C.; Yang, Y.L.; Humpf, H.U.; Maansson, M.; Keyzers, R.A.; Sims, A.C.; 214 Johnson, A.R.; Sidebottom, A.M.; Sedio, B.E.; Klitgaard, A.; Larson, C.B.; Boya P, C.A.; Torres-Mendoza, D.; Gonzalez, D.J.; Silva, D.B.; Marques, L.M.; Demarque, D.P.; Pociute, E.; O'Neill, E.C.; Briand, E.; Helfrich, E.J.N.; Granatosky, E.A.; Glukhov, E.; Ryffel, F.; Houson, H.; Mohimani, H.; Kharbush, J.J.; Zeng, 217 Y.; Vorholt, J.A.; Kurita, K.L.; Charusanti, P.; McPhail, K.L.; Nielsen, K.F.; Vuong, L.; Elfeki, M.; Traxler, M.F.; Engene, N.; Koyama, N.; Vining, O.B.; Baric, R.; Silva, R.R.; Mascuch, S.J.; Tomasi, S.; Jenkins, S.; 219 Macherla, V.; Hoffman, T.; Agarwal, V.; Williams, P.G.; Dai, J.; Neupane, R.; Gurr, J.; Rodríguez, A.M.C.; 220 Lamsa, A.; Zhang, C.; Dorrestein, K.; Duggan, B.M.; Almaliti, J.; Allard, P.M.; Phapale, P.; Nothias, L.F.; Alexandrov, T.; Litaudon, M.; Wolfender, J.L.; Kyle, J.E.; Metz, T.O.; Peryea, T.; Nguyen, D.T.; VanLeer, 222 D.; Shinn, P.; Jadhav, A.; Müller, R.; Waters, K.M.; Shi, W.; Liu, X.; Zhang, L.; Knight, R.; Jensen, P.R.; Palsson, B.Ø.; Pogliano, K.; Linington, R.G.; Gutiérrez, M.; Lopes, N.P.; Gerwick, W.H.; Moore, B.S.; Dorrestein, P.C.; Bandeira, N. Sharing and community curation of mass spectrometry data with Global 225 Natural Products Social Molecular Networking. Nature Biotechnology 2016, 34, 828 EP -. 226
- Ekpendu, T.O.; Akah, P.A.; Adesomoju, A.A.; Okogun, J.I. Antiinflammatory and Antimicrobial Activities of *Mitracarpus scaber* Extracts. *International Journal of Pharmacognosy* **1994**, 32, 191–196.
- Bisignano, G.; Sanogo, R.; Marino, A.; Aquino, R.; 'angelo, V.D.; Germano, M.P.; De Pasquale, R.; Pizza,
   C. Antimicrobial activity of *Mitracarpus scaber* extract and isolated constituents. *Letters in Applied Microbiology* 2000, 30, 105–108.
- Gbaguidi, F.; Accrombessi, G.; Moudachirou, M.; Quetin-Leclercq, J. HPLC quantification of two isomeric triterpenic acids isolated from Mitracarpus scaber and antimicrobial activity on Dermatophilus congolensis. *Journal of Pharmaceutical and Biomedical Analysis* **2005**, *39*, 990 995.

- Okunade, A.L.; Clark, A.M.; Hufford, C.D.; Oguntimein, B.O. Azaanthraquinone: An Antimicrobial Alkaloid from *Mitracarpus scaber*. *Planta Medica* **1999**, 65, 447–448.
- Harouna, H.; Faure, R.; Elias, R.; Debrauwer, L.; Saadou, M.; Balansard, G.; Boudon, G. Harounoside a pentalongin hydroquinone diglycoside from Mitracarpus scaber. *Phytochemistry* **1995**, *39*, 1483 1484.
- Pialat, J.P.; Hoffmann, P.; Moulis, C.; Fouraste, I.; Labidalle, S. Synthesis and Extraction of Pentalongin, A
   Naphthoquinoid From Mitracarpus Scaber. *Natural Product Letters* 1998, 12, 23–30.
- Burgess, K.; Borutzki, Y.; Rankin, N.; Daly, R.; Jourdan, F. MetaNetter 2: A Cytoscape plugin for ab initio network analysis and metabolite feature classification. *Journal of Chromatography B* **2017**.
- Menachery, S.P.M.; Laprévote, O.; Nguyen, T.P.; Aravind, U.K.; Gopinathan, P.; Aravindakumar, C.T.
   Identification of position isomers by energy-resolved mass spectrometry. *Journal of Mass Spectrometry* 2015, 50, 944–950.
- Xia, B.; Zhou, Y.; Liu, X.; Xiao, J.; Liu, Q.; Gu, Y.; Ding, L. Use of electrospray ionization ion-trap tandem
   mass spectrometry and principal component analysis to directly distinguish monosaccharides. *Rapid Communications in Mass Spectrometry* 2012, 26, 1259–1264.
- Giner, J.L.; Feng, J.; Kiemle, D.J. NMR Tube Degradation Method for Sugar Analysis of Glycosides. *Journal of Natural Products* 2016, 79, 2413–2417. PMID: 27603739.
- 14. Genta-Jouve, G.; Weinberg, L.; Cocandeau, V.; Maestro, Y.; Thomas, O.P.; Holderith, S. Revising the
   Absolute Configurations of Coatlines via Density Functional Theory Calculations of Electronic Circular
   Dichroism Spectra. Chirality 2013, 25, 180–184.
- Han, A.R.; Park, S.R.; Park, J.W.; Lee, E.Y.; Kim, D.M.; Kim, B.G.; Yoon, Y.J. Biosynthesis of Glycosylated
   Derivatives of Tylosin in Streptomyces venezuelae. J. Microbiol. Biotechnol 2011, 21, 613–616.
- De Castro, C.; Kenyon, J.J.; Cunneen, M.M.; Molinaro, A.; Holst, O.; Skurnik, M.; Reeves, P.R. The O-specific polysaccharide structure and gene cluster of serotype O:12 of the *Yersinia pseudotuberculosis* complex, and the identification of a novel l-quinovose biosynthesis gene. *Glycobiology* **2013**, 23, 346–353.
- Baggiolini, M.; Clark-Lewis, I. Interleukin-8, a chemotactic and inflammatory cytokine. *FEBS Letters* **1992**, 307, 97–101.
- Pease, J.E.; Sabroe, I. The Role of Interleukin-8 and its Receptors in Inflammatory Lung Disease. *American Journal of Respiratory Medicine* **2002**, *1*, 19–25.
- 263 19. of EGCG has been measured on a previous experiment., T.I.
- Réfrégiers, M.; Wien, F.; Ta, H.P.; Premvardhan, L.; Bac, S.; Jamme, F.; Rouam, V.; Lagarde, B.; Polack, F.;
   Giorgetta, J.L.; Ricaud, J.P.; Bordessoule, M.; Giuliani, A. DISCO synchrotron-radiation circular-dichroism
   endstation at SOLEIL. *Journal of Synchrotron Radiation* 2012, 19, 831–835.
- Giuliani, A.; Jamme, F.; Rouam, V.; Wien, F.; Giorgetta, J.L.; Lagarde, B.; Chubar, O.; Bac, S.; Yao, I.; Rey,
   S.; Herbeaux, C.; Marlats, J.L.; Zerbib, D.; Polack, F.; Réfrégiers, M. DISCO: A low-energy multipurpose beamline at synchrotron SOLEIL. *Journal of Synchrotron Radiation* 2009, 16, 835–841.
- Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.;
  Barone, V.; Petersson, G.A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A.V.; Bloino, J.; Janesko, B.G.;
  Gomperts, R.; Mennucci, B.; Hratchian, H.P.; Ortiz, I.V.; Izmaylov, A.F.; Sonnenberg, I.L.; Williams-Young,
- Gomperts, R.; Mennucci, B.; Hratchian, H.P.; Ortiz, J.V.; Izmaylov, A.F.; Sonnenberg, J.L.; Williams-Young, D.; Ding, F.; Lipparini, F.; Egidi, F.; Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; Ranasinghe, D.;
- Zakrzewski, V.G.; Gao, J.; Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda,
- R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Throssell, K.;
- Montgomery, Jr., J.A.; Peralta, J.E.; Ogliaro, F.; Bearpark, M.J.; Heyd, J.J.; Brothers, E.N.; Kudin, K.N.;
- Staroverov, V.N.; Keith, T.A.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.P.; Burant, J.C.; Iyengar, S.S.; Tomasi, J.; Cossi, M.; Millam, J.M.; Klene, M.; Adamo, C.; Cammi, R.; Ochterski, J.W.; Martin,
- R.L.; Morokuma, K.; Farkas, O.; Foresman, J.B.; Fox, D.J. Gaussian~16 Revision B.01, 2016. Gaussian Inc.
  Wallingford CT.
- <sup>281</sup> 23. Bruhn, T.; Schaumlöffel, A.; Hemberger, Y.; Bringmann, G. SpecDis: Quantifying the Comparison of Calculated and Experimental Electronic Circular Dichroism Spectra. *Chirality* **2013**, 25, 243–249.
- <sup>283</sup> 24. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2018.
- Sample Availability: Samples of the compounds 1 and 2 are available from the authors.